London, UK (PRWEB) September 01, 2015
Pharmaceutical companies are constantly seeking better therapeutic options to efficiently cure and prevent different malignancies. Some options for cancer treatment are available belonging to various molecule classes. Different cancers have different pathophysiological properties due to which distinctive approach is necessary for effective treatment. Several molecules have been discovered out of which CD antigens have been found to play a crucial role in the progression and proliferation of cancer. Investigators are attempting to assign various functions to CD antigens by performing extensive R&D.
The CD antigen cancer market is projected to see the introduction of a number of products which will assist the pharmacos in generating considerable revenues. The growth in the sector is expected to be driven by the surging demand for improved therapeutics, large unmet medical needs and a record number of cancer patients. Increased funding in R&D alongside the utilisation of cutting-edge technology will also assist in boosting their market shares worldwide. Manifold novel CD antigen cancer therapeutics are currently at various clinical trial phases which would expand their market shares. In spite of these facts they have higher prices and their production is difficult but utilisation of advanced technology in tandem with streamlining of different processes are likely to clear this barrier. In this manner, the future of CD antigen cancer therapeutics looks bright owing to their superior pharmacological profiles.
Comprehensive research report “Cancer CD Antigens Inhibitors Therapy Market & Pipeline Insight 2015” prepared by Kuick Research is now available at MarketPublishers.com.
Title: Cancer CD Antigens Inhibitors Therapy Market & Pipeline Insight 2015
Published: August, 2015
Price: US$ 3,000.00
The report provides a guide to the nomenclature and classification of CD antigens, and also the mechanism of CD antigen cancer therapeutics. It further proceeds with an overview of the current cancer CD antigen therapy market and pipeline; limelights the market dynamics covering major driving factors and challenges; examines the future prospects of the CD antigen cancer therapeutics; The publication presents a deep overview of the cancer CD antigen inhibitors clinical pipeline ( 207 drug products, by company, indication and phase), covers the marketed cancer CD antigen inhibitors (27 drugs), 70 cancer CD antigen inhibitors in pre-clinical phase; cancer CD antigens clinical pipeline dominated by CD20 antigen (44 drugs). Insights into the discontinued and suspended cancer CD antigen inhibitors are provided, too. The extensive competitive landscape review including profiles of the dominant players can be found in the report as well.
Key Topics Discussed:
- information on the nomenclature and classification of CD antigens;
- mechanism of CD antigen cancer therapeutics;
- review of the cancer CD antigen therapy marketplace;
- all-encompassing review of the cancer CD antigen inhibitors clinical pipeline by indication, company, and stage;
- insights into of the 207 drugs in clinical pipeline;
- overview of the 27 marketed cancer CD antigen inhibitors;
- examination of the 70 cancer CD antigen inhibitors in pre-clinical stage;
- assessment of the cancer CD antigens clinical pipeline led by CD20 antigen (44 drugs);
- key player profiles.
More studies by the publisher can be found at Kuick Research page.